Greenwich Stock Performance

GLSI -  USA Stock  

USD 8.50  0.55  6.92%

The company retains a Market Volatility (i.e., Beta) of 0.0486, which attests to not very significant fluctuations relative to the market. Let's try to break down what Greenwich's beta means in this case. As returns on the market increase, Greenwich Lifesciences returns are expected to increase less than the market. However, during the bear market, the loss on holding Greenwich Lifesciences will be expected to be smaller as well. Even though it is essential to pay attention to Greenwich Lifesciences current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Greenwich Lifesciences exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Greenwich Lifesciences has an expected return of -1.16%. Please be advised to check out Greenwich Lifesciences value at risk, and the relationship between the jensen alpha and skewness to decide if Greenwich Lifesciences performance from the past will be repeated at some point in the near future.
  
Refresh
Greenwich Performance
0 of 100
Over the last 90 days Greenwich Lifesciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in June 2022. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more

Greenwich Price Channel

Quick Ratio81.86
Fifty Two Week Low7.88
Target High Price78.00
Fifty Two Week High48.96
Target Low Price78.00

Greenwich Lifesciences Relative Risk vs. Return Landscape

If you would invest  1,949  in Greenwich Lifesciences on February 27, 2022 and sell it today you would lose (1,099)  from holding Greenwich Lifesciences or give up 56.39% of portfolio value over 90 days. Greenwich Lifesciences is currently does not generate positive expected returns and assumes 4.6688% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Greenwich, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Greenwich Lifesciences is expected to under-perform the market. In addition to that, the company is 3.48 times more volatile than its market benchmark. It trades about -0.25 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.02 per unit of volatility.

Greenwich Lifesciences Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Greenwich Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Greenwich Lifesciences, and traders can use it to determine the average amount a Greenwich Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2484

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsGLSI
Estimated Market Risk
 4.67
  actual daily
 
 40 %
of total potential
 
4040
Expected Return
 -1.16
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.25
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Greenwich Lifesciences is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Greenwich Lifesciences by adding it to a well-diversified portfolio.

About Greenwich Lifesciences Performance

To evaluate Greenwich Lifesciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Greenwich Lifesciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Greenwich Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Greenwich Lifesciences stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Greenwich's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.16) (0.17) 
Return on Average Equity(0.16) (0.16) 
Return on Invested Capital 8.44  7.81 
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Things to note about Greenwich Lifesciences

Checking the ongoing alerts about Greenwich Lifesciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Greenwich Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Greenwich Lifesciences Alerts

Equity Alerts and Improvement Suggestions

Greenwich Lifesciences generated a negative expected return over the last 90 days
Greenwich Lifesciences has high historical volatility and very poor performance
Net Loss for the year was (5.94 M).
Greenwich Lifesciences currently holds about 19.74 M in cash with (5.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 77.0% of the company shares are held by company insiders
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.